Date: March 27, 2024

To,	To,
The Manager, Listing Department,	The Department of Corporate Service,
National Stock Exchange of India Limited,	**BSE Limited,**
Exchange Plaza, C – 1, Block – G,	1st Floor, New Trading Ring,
Bandra – Kurla Complex, Bandra (E),	Rotunda Building, Phiroze Jeejeebhoy Tower,
Mumbai-400 051.	Dalal Street, Mumbai – 400 001.
Scrip Code – LINCOLN	**Scrip Code – 531633**

Dear Sir/Madam,

<u>**Sub: Intimation of Closure of Trading Window**</u>

We would like to inform that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendment thereto ("Regulations") and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company, the Trading Window for dealing in the securities of the Company shall remain closed from April 01, 2024 till 48 hours after the declaration of the Audited Financial Results of the Company, for the quarter and year ended March 31, 2024.

The date of meeting of the Board of Directors, to approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2024 will be informed in due course.

Accordingly all Directors, Senior Management Personnel, Promoter and Promoter Group of the Company and its subsidiaries including their Immediate Relatives and other Connected Persons are advised not to trade in securities of the Company during the aforesaid period of closure of trading window.

We request you to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LTD

_____

TRUSHA K. SHAH
COMPANY SECRETARY &
COMPLIANCE OFFICER